Study guide
3.4 ACMG/AMP Variant Classification
Certified Genetic Counselor CGC
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 About the CGC Exam & Credential 1.2 Eligibility Categories, Application & Fees 1.3 Scoring, Pass Rate & Test-Day Logistics
2 Domain 1A: Clinical Information
1.4 Medical & Pregnancy History 1.5 Teratogens, Exposures & Non-Genetic Risk Factors 1.6 Differential Diagnosis, Indication & Referral Urgency 1.7 Referral Triage, Case Preparation & Records Review
3 Domain 1B: Human Development
1.8 Fetal Development 1.9 Developmental Milestones 1.10 Physical & Psychological Development
4 Domain 1C: Chromosomal & Contiguous Gene Syndromes
1.11 Aneuploidy Syndromes (Down, Turner, Klinefelter, Edwards, Patau) 1.12 Microdeletion Syndromes (22q11.2, Williams, and Related) 1.13 Imprinting Disorders (PWS, Angelman, Beckwith-Wiedemann, Russell-Silver)
5 Domain 1C: Hereditary Cancer Syndromes
1.14 Hereditary Breast & Ovarian Cancer (BRCA1/2, PALB2, and Related) 1.15 Lynch Syndrome & Polyposis Syndromes 1.16 Li-Fraumeni, VHL, MEN, NF1/NF2 & Other Cancer Predisposition
6 Domain 1C: Metabolic, Neuromuscular & Multisystem Conditions
1.17 Inborn Errors of Metabolism & Storage Disorders 1.18 Neuromuscular Disease & Fragile X Spectrum 1.19 Connective Tissue & Cardiovascular Genetics 1.20 Screening, Surveillance, Treatment & Diagnostic Strategy Framework
7 Domain 2A: Pedigree & Risk Assessment
2.1 Family History, Pedigree Construction & Analysis 2.2 Mendelian Risk Calculations 2.3 Bayesian Risk Calculations 2.4 Empiric Risk, Multifactorial Recurrence & Risk-Assessment Models 2.5 Residual Risk & Follow-Up Medical Plans
8 Domain 2B: Inheritance Principles
2.6 Mendelian Inheritance Patterns 2.7 Non-Mendelian Inheritance (Mitochondrial, Imprinting, Multifactorial) 2.8 Penetrance, Expressivity, Anticipation & Heterogeneity 2.9 Mosaicism, X-Inactivation & Epigenetic Modifiers of Phenotype
9 Domain 2B: Population Genetics & Variation
2.10 Population Genetics, HWE & Quantitative Genetics 2.11 Human Genetic Variation & Disease Susceptibility
10 Domain 3A: Test Methodologies
3.1 Karyotype, FISH & Chromosomal Microarray 3.2 Molecular Diagnostics (Sanger, NGS Panels, WES, WGS, MLPA) 3.3 Sample Types, Clinical Context & Predictive Metrics
11 Domain 3A: Variant Interpretation
3.4 ACMG/AMP Variant Classification 3.5 Reanalysis, Reclassification & Validity/Utility Framework
12 Domain 3B: Testing Options
3.6 Diagnostic Testing Strategies 3.7 Screening Testing (including Newborn Screening) 3.8 Predictive & Pre-symptomatic Testing 3.9 Carrier, Somatic & Research Testing
13 Domain 3C: Reproductive Risk Management
3.10 Assisted Reproductive Technologies & PGT 3.11 Family Planning & Reproductive Options 3.12 Prenatal Screening (NIPT, Serum Markers) 3.13 Prenatal Diagnostic Procedures (CVS, Amniocentesis)
14 Domain 4A: Counseling Foundations
4.1 Contracting & Interviewing Techniques 4.2 Psychosocial Assessment, Follow-Up & Family Dynamics 4.3 Client Personal Identity & Cultural Humility
15 Domain 4A: Theories, Coping & Dynamics
4.4 Counseling Theories & Models (REM, Trajectory) 4.5 Defense Mechanisms, Coping & Decision-Making Styles 4.6 Grief, Perinatal Loss & Crisis Response 4.7 Self-Awareness & Client-Counselor Dynamics
16 Domain 4B: Communication & Education
4.8 Delivery Modes & Working with Interpreters 4.9 Risk Communication Theories & Models 4.10 Results Delivery & Long-Term Follow-Up 4.11 Health Literacy, Informed Consent & Informed Decision Making
17 Domain 5A–B: Finance & Client Resources
5.1 Insurance Policies, Billing & Letters of Medical Necessity 5.2 Billing, Coding & Reimbursement Compliance 5.3 Client Resources, Appropriateness & Timely Delivery
18 Domain 5C: Legal & Regulatory Requirements
5.4 GINA & Genetic Non-Discrimination Legislation 5.5 Privacy, Confidentiality, Documentation & Genomic Data Security 5.6 Human-Subjects Research Standards & Patient Access to Information 5.7 CLIA, Laboratory-Developed Tests & FDA Oversight 5.8 Genomic Data Security, DTC Testing & Data Sharing
19 Domain 5D: Professional Frameworks
5.9 NSGC Code of Ethics & Ethical Decision Making 5.10 Scope of Practice, Clinical Supervision & Conflict of Interest 5.11 Licensure, Credentialing & Maintaining the CGC Credential 5.12 Evidence-Based Practice & Professional/Public Education
20 Integration & Exam Strategy
6.1 Integrating Domains in Case-Based Practice & Exam Strategy
3.4 ACMG/AMP Variant Classification
Key Takeaways Explain This Topic AI
ACMG/AMP uses a five-tier system—Pathogenic (P), Likely Pathogenic (LP), Variant of Uncertain Significance (VUS), Likely Benign (LB), and Benign (B)—based on combined evidence criteria, not a single test result
PVS1 (null variant in a gene where loss of function is a known mechanism), PS1–PS4 (strong), PM2 (rarity in population databases), and PP3 (computational/predictive support) are high-yield evidence families counselors must recognize on reports
Benign evidence (BS/BP codes) can outweigh weak pathogenic signals; classification is a balance of conflicting criteria, not a checklist that always upgrades to Pathogenic
VUS counseling emphasizes that uncertain significance is not a diagnosis, medical management should follow phenotype and established guidelines rather than the VUS alone, and reclassification over time is expected
Genetic counselors translate lab classifications into clinical action: cascade testing for P/LP, phenotype-driven care and periodic review for VUS, and reassurance with residual-risk framing for LB/B in the right context
Last updated: August 2026
3.4 ACMG/AMP Variant Classification
Quick Answer: Sequence variants are classified in a five-tier ACMG/AMP system — Pathogenic (P) , Likely Pathogenic (LP) , VUS , Likely Benign (LB) , Benign (B) —by combining weighted evidence codes (e.g., PVS1 , PS1–4 , PM2 , PP3 , and BS/BP families). Counselors act on P/LP for diagnosis and cascade testing, treat VUS as uncertain (not a diagnosis), and avoid medicalizing LB/B findings.
Domain 3A items test whether you can read a molecular report, explain what the lab’s category means for the patient, and choose the next counseling or testing step. You do not need to recite every evidence code; you need application : which codes move a call toward pathogenic or benign, when a VUS should not drive surgery or prenatal decisions alone, and how to talk about uncertainty without false certainty.
The Five-Tier System
Clinical laboratories interpreting Mendelian sequence variants (germline) typically follow the 2015 ACMG/AMP framework (with gene- and disease-specific refinements from ClinGen and specialty societies). The five categories are designed for clinical reporting , not research curiosity labels.
Tier Abbreviation Clinical meaning for counseling
Pathogenic P Sufficient evidence the variant causes disease in the stated context; supports diagnosis when phenotype fits
Likely Pathogenic LP High likelihood of pathogenicity (commonly framed as ≥90% certainty in the original framework); often managed like P for cascade testing when phenotype aligns
- Variant of Uncertain Significance VUS Evidence insufficient or conflicting; not a positive diagnostic result
- Likely Benign LB High likelihood the variant is not disease-causing in this context
- Benign B Sufficient evidence the variant is not pathogenic
Exam trap: Equating “rare” with “pathogenic.” Rarity (often captured conceptually under population-data criteria such as PM2 ) is only one piece of evidence. Common polymorphisms in gnomAD/population databases frequently support benign classification when allele frequency is too high for the disorder’s prevalence and penetrance model.
Another trap: Treating LP as “maybe” in the same way as VUS. LP is intentionally closer to P for clinical action in many settings (including family variant testing), whereas VUS is explicitly not used alone to establish a molecular diagnosis or to offer relatives predictive testing as if the variant were known disease-causing.
Evidence Codes You Must Recognize Conceptually
Codes are lettered by strength and direction: P = pathogenic-leaning, B = benign-leaning; VS/S/M/P ≈ very strong / strong / moderate / supporting. Specialty rules (e.g., for BRCA1/2 , hearing loss, RASopathies) can modify how codes are applied—know that gene-specific guidance can override generic application .
Code family (examples) Core idea Counselor translation
PVS1 Predicted null variant (nonsense, frameshift, canonical ±1/2 splice, initiation codon, single- or multi-exon deletion) in a gene where loss of function is a known disease mechanism Strong push toward pathogenicity—but only if LoF is established for that gene/disease; last-exon or NMD-escape variants may weaken PVS1
PS1 Same amino acid change as a previously established pathogenic variant (different nucleotide possible) “Known bad missense at this residue” type support
PS2 / PM6 De novo (maternity/paternity confirmed vs assumed) in a patient with the phenotype and no family history Powerful in severe pediatric phenotypes; confirm parental relationships when the report claims confirmed de novo
PS3 Well-established functional studies show a damaging effect Lab or literature assays—not a patient’s clinical severity alone
PS4 Prevalence in affected individuals statistically increased vs controls More common in case–control / cohort evidence than in a single-family session
PM2 Absent or extremely rare in population databases Supports pathogenicity only as moderate (or adjusted) evidence—never sufficient alone
PP3 Multiple lines of computational evidence support a deleterious effect (in silico) Supporting at most in standard use; do not oversell “the computer says pathogenic”
BS / BP families Strong or supporting benign evidence (e.g., high allele frequency, functional studies showing no effect, co-occurrence with a known pathogenic variant in trans for recessive disease, in silico benign predictions) Can neutralize or outweigh weak pathogenic codes → LB/B or keep as VUS if conflict remains
How counselors use this on a report: You rarely recalculate the lab’s points from scratch on the CGC exam. You interpret the narrative : “Classified LP based on a predicted null variant in a LoF gene (PVS1-type evidence) plus absence from population databases and de novo occurrence.” Your job is to connect that logic to who should be offered testing next and what not to do with a VUS.
Worked Scenario: Null Variant vs Missense VUS
Scenario A — LP/P leaning null. A child with a classic haploinsufficiency syndrome has a heterozygous frameshift in a gene where LoF is an established mechanism. Parental studies show the variant is de novo (relationships confirmed). Population databases show absence. Expect a P or LP call driven by PVS1-type plus de novo and rarity evidence. Counseling: the molecular result supports the clinical diagnosis ; offer cascade testing only if relevant (often limited if de novo and parents negative in blood—still mention germline mosaicism residual risk as in Mendelian teaching).
Scenario B — Missense VUS. An adult with an ambiguous connective-tissue phenotype has a novel heterozygous missense in a large panel gene. Frequency is ultra-rare (PM2-leaning), in silico tools are mixed-to-damaging (PP3-leaning), no functional data, and the variant is inherited from an unaffected parent. Conflicting or insufficient evidence → VUS . Counseling: the finding does not confirm a hereditary syndrome; do not recommend prophylactic surgery or predictive testing of relatives solely because of this VUS; manage based on clinical diagnostic criteria and family history; discuss that labs reclassify over time.
Scenario C — Benign frequency reality check. A “candidate” variant present at 2% allele frequency in a large outbred population database is almost never the cause of a rare highly penetrant Mendelian disease. Expect LB/B via frequency-based benign criteria regardless of a scary-sounding gene name on a large panel.
VUS Counseling Essentials
VUS sessions are high-stakes communication items on the CGC exam.
Define uncertainty plainly: “The lab does not have enough evidence to say whether this spelling change causes disease.”
Separate result from care plan: Screening, surgery, and prenatal decisions should follow phenotype, established diagnostic criteria, and guidelines —not the VUS alone.
Family testing limits: Do not offer relatives “predictive” testing for a VUS as if a negative result clears risk or a positive result confirms diagnosis. Segregation studies may be research-adjacent or lab-directed in limited circumstances; frame carefully.
Set expectations for change: Variants are reclassified; offer a plan for how the patient will learn of updates (portal, recontact policy, periodic reanalysis—see 3.5).
Psychosocial honesty: Patients often hear “variant” as “positive.” Check understanding and correct the diagnostic implication.
From Classification to Clinical Action
Report call Typical counselor actions
P / LP (phenotype fits) Use as molecular confirmation or strong support; discuss inheritance, cascade testing of relatives for the known familial variant , reproductive options, and management per gene/condition guidelines
P / LP (phenotype poor fit) Pause—consider alternate diagnoses, secondary findings policy, or lab error/misattribution; do not force a mismatched syndrome onto the patient
VUS Phenotype-driven care; document uncertainty; plan for reclassification/reanalysis; avoid cascade “predictive” framing
LB / B Generally not used to explain the patient’s disease; continue diagnostic workup if phenotype remains unexplained
Secondary findings (e.g., ACMG SF gene list on exome/genome) follow consent and lab policy—classification tiers still apply, but disclosure and actionability add a counseling layer separate from the primary indication.
Master the tiers and the behavioral difference between LP and VUS; that distinction drives most board vignettes more than memorizing the full code catalog.